282 related articles for article (PubMed ID: 28393622)
1. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.
Hrynchak I; Sousa E; Pinto M; Costa VM
Drug Metab Rev; 2017 May; 49(2):158-196. PubMed ID: 28393622
[TBL] [Abstract][Full Text] [Related]
2. The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.
Reis-Mendes AF; Sousa E; de Lourdes Bastos M; Costa VM
Curr Drug Metab; 2015; 17(1):75-90. PubMed ID: 26526839
[TBL] [Abstract][Full Text] [Related]
3. Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.
Reis-Mendes A; Gomes AS; Carvalho RA; Carvalho F; Remião F; Pinto M; Bastos ML; Sousa E; Costa VM
Arch Toxicol; 2017 Apr; 91(4):1871-1890. PubMed ID: 27629428
[TBL] [Abstract][Full Text] [Related]
4. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.
Moudgil R; Yeh ET
Can J Cardiol; 2016 Jul; 32(7):863-870.e5. PubMed ID: 27117975
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease in adult survivors of childhood cancer.
Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
[TBL] [Abstract][Full Text] [Related]
7. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
9. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.
Reis-Mendes A; Carvalho F; Remião F; Sousa E; Bastos ML; Costa VM
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30862114
[TBL] [Abstract][Full Text] [Related]
10. Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.
Biasillo G; Cipolla CM; Cardinale D
Curr Oncol Rep; 2017 Aug; 19(8):55. PubMed ID: 28707189
[TBL] [Abstract][Full Text] [Related]
11. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced mitochondrial dysfunction and cardiotoxicity.
Varga ZV; Ferdinandy P; Liaudet L; Pacher P
Am J Physiol Heart Circ Physiol; 2015 Nov; 309(9):H1453-67. PubMed ID: 26386112
[TBL] [Abstract][Full Text] [Related]
16. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S84-92. PubMed ID: 27183529
[TBL] [Abstract][Full Text] [Related]
17. In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria.
van Acker FA; van Acker SA; Haenen GR; Bast A; van der Vijgh WJ
Anticancer Res; 2000; 20(6B):4483-7. PubMed ID: 11205292
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
19. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of cardiotoxicity from antineoplastic therapy.
Chanan-Khan A; Srinivasan S; Czuczman MS
J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
